These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 21948088)

  • 21. Effects of N-[N-(3, 5-difluorophenacetyl-L-alanyl)]-S-phenylglycine t-butyl ester (DAPT) on cell proliferation and apoptosis in Ishikawa endometrial cancer cells.
    Mori M; Miyamoto T; Yakushiji H; Ohno S; Miyake Y; Sakaguchi T; Hattori M; Hongo A; Nakaizumi A; Ueda M; Ohno E
    Hum Cell; 2012 Mar; 25(1):9-15. PubMed ID: 22189483
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacological targeting of the ephrin receptor kinase signalling by GLPG1790 in vitro and in vivo reverts oncophenotype, induces myogenic differentiation and radiosensitizes embryonal rhabdomyosarcoma cells.
    Megiorni F; Gravina GL; Camero S; Ceccarelli S; Del Fattore A; Desiderio V; Papaccio F; McDowell HP; Shukla R; Pizzuti A; Beirinckx F; Pujuguet P; Saniere L; der Aar EV; Maggio R; De Felice F; Marchese C; Dominici C; Tombolini V; Festuccia C; Marampon F
    J Hematol Oncol; 2017 Oct; 10(1):161. PubMed ID: 28985758
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A high Notch pathway activation predicts response to γ secretase inhibitors in proneural subtype of glioma tumor-initiating cells.
    Saito N; Fu J; Zheng S; Yao J; Wang S; Liu DD; Yuan Y; Sulman EP; Lang FF; Colman H; Verhaak RG; Yung WK; Koul D
    Stem Cells; 2014 Jan; 32(1):301-12. PubMed ID: 24038660
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recent Insights into Notch Signaling in Embryonal Rhabdomyosarcoma.
    Conti B; Slemmons KK; Rota R; Linardic CM
    Curr Drug Targets; 2016; 17(11):1235-44. PubMed ID: 26343114
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthetic lethality through combined Notch-epidermal growth factor receptor pathway inhibition in basal-like breast cancer.
    Dong Y; Li A; Wang J; Weber JD; Michel LS
    Cancer Res; 2010 Jul; 70(13):5465-74. PubMed ID: 20570903
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Atonal homolog 1 is required for growth and differentiation effects of notch/gamma-secretase inhibitors on normal and cancerous intestinal epithelial cells.
    Kazanjian A; Noah T; Brown D; Burkart J; Shroyer NF
    Gastroenterology; 2010 Sep; 139(3):918-28, 928.e1-6. PubMed ID: 20621629
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Constitutive activation of MET signaling impairs myogenic differentiation of rhabdomyosarcoma and promotes its development and progression.
    Skrzypek K; Kusienicka A; Szewczyk B; Adamus T; Lukasiewicz E; Miekus K; Majka M
    Oncotarget; 2015 Oct; 6(31):31378-98. PubMed ID: 26384300
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Notch signaling is involved in neurogenic commitment of human periodontal ligament-derived mesenchymal stem cells.
    Osathanon T; Manokawinchoke J; Nowwarote N; Aguilar P; Palaga T; Pavasant P
    Stem Cells Dev; 2013 Apr; 22(8):1220-31. PubMed ID: 23379739
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antagonistic regulation of p57kip2 by Hes/Hey downstream of Notch signaling and muscle regulatory factors regulates skeletal muscle growth arrest.
    Zalc A; Hayashi S; Auradé F; Bröhl D; Chang T; Mademtzoglou D; Mourikis P; Yao Z; Cao Y; Birchmeier C; Relaix F
    Development; 2014 Jul; 141(14):2780-90. PubMed ID: 25005473
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CASZ1 induces skeletal muscle and rhabdomyosarcoma differentiation through a feed-forward loop with MYOD and MYOG.
    Liu Z; Zhang X; Lei H; Lam N; Carter S; Yockey O; Xu M; Mendoza A; Hernandez ER; Wei JS; Khan J; Yohe ME; Shern JF; Thiele CJ
    Nat Commun; 2020 Feb; 11(1):911. PubMed ID: 32060262
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quantification of gamma-secretase modulation differentiates inhibitor compound selectivity between two substrates Notch and amyloid precursor protein.
    Yang T; Arslanova D; Gu Y; Augelli-Szafran C; Xia W
    Mol Brain; 2008 Nov; 1():15. PubMed ID: 18983676
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MEK/ERK inhibitor U0126 affects in vitro and in vivo growth of embryonal rhabdomyosarcoma.
    Marampon F; Bossi G; Ciccarelli C; Di Rocco A; Sacchi A; Pestell RG; Zani BM
    Mol Cancer Ther; 2009 Mar; 8(3):543-51. PubMed ID: 19258428
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The NOTCH1/SNAIL1/MEF2C Pathway Regulates Growth and Self-Renewal in Embryonal Rhabdomyosarcoma.
    Ignatius MS; Hayes MN; Lobbardi R; Chen EY; McCarthy KM; Sreenivas P; Motala Z; Durbin AD; Molodtsov A; Reeder S; Jin A; Sindiri S; Beleyea BC; Bhere D; Alexander MS; Shah K; Keller C; Linardic CM; Nielsen PG; Malkin D; Khan J; Langenau DM
    Cell Rep; 2017 Jun; 19(11):2304-2318. PubMed ID: 28614716
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Notch effector Hey1 associates with myogenic target genes to repress myogenesis.
    Buas MF; Kabak S; Kadesch T
    J Biol Chem; 2010 Jan; 285(2):1249-58. PubMed ID: 19917614
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A dysfunctional miR-1-TRPS1-MYOG axis drives ERMS by suppressing terminal myogenic differentiation.
    Hüttner SS; Henze H; Elster D; Koch P; Anderer U; von Eyss B; von Maltzahn J
    Mol Ther; 2023 Sep; 31(9):2612-2632. PubMed ID: 37452493
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of selective gamma-secretase inhibitor PF-03084014 for its antitumor efficacy and gastrointestinal safety to guide optimal clinical trial design.
    Wei P; Walls M; Qiu M; Ding R; Denlinger RH; Wong A; Tsaparikos K; Jani JP; Hosea N; Sands M; Randolph S; Smeal T
    Mol Cancer Ther; 2010 Jun; 9(6):1618-28. PubMed ID: 20530712
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Upregulation of Notch pathway molecules in oral squamous cell carcinoma.
    Hijioka H; Setoguchi T; Miyawaki A; Gao H; Ishida T; Komiya S; Nakamura N
    Int J Oncol; 2010 Apr; 36(4):817-22. PubMed ID: 20198324
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SPRY2 is a novel MET interactor that regulates metastatic potential and differentiation in rhabdomyosarcoma.
    Saini M; Verma A; Mathew SJ
    Cell Death Dis; 2018 Feb; 9(2):237. PubMed ID: 29445192
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Requirement of Notch activation during regeneration of the intestinal epithelia.
    Okamoto R; Tsuchiya K; Nemoto Y; Akiyama J; Nakamura T; Kanai T; Watanabe M
    Am J Physiol Gastrointest Liver Physiol; 2009 Jan; 296(1):G23-35. PubMed ID: 19023031
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The muscle-specific microRNA miR-206 blocks human rhabdomyosarcoma growth in xenotransplanted mice by promoting myogenic differentiation.
    Taulli R; Bersani F; Foglizzo V; Linari A; Vigna E; Ladanyi M; Tuschl T; Ponzetto C
    J Clin Invest; 2009 Aug; 119(8):2366-78. PubMed ID: 19620785
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.